Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis.

Circulation. Cardiovascular quality and outcomes - 1 Apr 2018

Jarmul Jamie, Pletcher Mark J, Hassmiller Lich Kristen, Wheeler Stephanie B, Weinberger Morris, Avery Christy L, Jonas Daniel E, Earnshaw Stephanie, Pignone Michael

Abstract excerpt

BACKGROUND: It is unclear whether testing for novel risk factors, such as a cardiovascular genetic risk score (cGRS), improves clinical decision making or health outcomes when used for targeting statin initiation in the primary prevention of atherosclerotic cardiovascular disease (ASCVD). Our objective was to estimate the cost-effectiveness of cGRS testing to inform clinical decision making about statin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Decision-Making
Share to Decision Support Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decision Trees

Share to Drug Costs

Share to Health Status

Share to Models, Economic

Share to Primary Prevention

Share to Quality-Adjusted Life Years

Source

Identifiers

PMID: 29650716
DOI: 10.1161/CIRCOUTCOMES.117.004171

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis.PMID 29650716Read ↗

An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients.Semantic proximity Read ↗

Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome.Semantic proximity Read ↗

Marginal role for 53 common genetic variants in cardiovascular disease prediction.Semantic proximity Read ↗

Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial.Semantic proximity Read ↗

Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial).Semantic proximity Read ↗

Optimal cholesterol treatment plans and genetic testing strategies for cardiovascular diseases.Semantic proximity Read ↗

Cost-effectiveness of cascade genetic testing for familial hypercholesterolemia in the United States: A simulation analysisSemantic proximity Read ↗

Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.Semantic proximity Read ↗

Impact of genetic testing on complex diseases.Semantic proximity Read ↗

Incremental value of a genetic risk score for the prediction of new vascular events in patients with clinically manifest vascular disease.Semantic proximity Read ↗

Using a genetic risk score to calculate the optimal age for an individual to undergo coronary artery calcium screening.Semantic proximity Read ↗

Cost-effectiveness of alternative cascade screening strategies for familial hypercholesterolemia with realistic cascade screening acceptance rates and use of high-cost drugsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.